These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 39365506)

  • 1. Cost-Effectiveness of Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Vaccine During Pregnancy for Prevention of Respiratory Syncytial Virus Among Infants in Argentina.
    Rey-Ares L; Averin A; Zuccarino N; Vega CG; Kutrieb E; Quinn E; Atwood M; Weycker D; Law AW
    Infect Dis Ther; 2024 Nov; 13(11):2363-2376. PubMed ID: 39365506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness Analysis of Maternal Respiratory Syncytial Virus Vaccine in Protecting Infants from RSV Infection in Japan.
    Ishiwada N; Akaishi R; Kobayashi Y; Togo K; Yonemoto N; Matsuo M; Kaneko S; Law AW; Kamei K
    Infect Dis Ther; 2024 Jul; 13(7):1665-1682. PubMed ID: 38834858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness Analysis of Maternal Immunization with RSVpreF Vaccine for the Prevention of Respiratory Syncytial Virus Among Infants in Spain.
    Álvarez Aldean J; Rivero Calle I; Rodríguez Fernández R; Aceituno Mata S; Bellmunt A; Prades M; Law AW; López-Ibáñez de Aldecoa A; Méndez C; García Somoza ML; Soto J; Lozano V
    Infect Dis Ther; 2024 Jun; 13(6):1315-1331. PubMed ID: 38733493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of bivalent RSVpreF maternal vaccination to prevent RSV illness in Japanese infants: Subset analysis from the pivotal randomized phase 3 MATISSE trial.
    Otsuki T; Akada S; Anami A; Kosaka K; Munjal I; Baber J; Shoji Y; Aizawa M; Swanson KA; Gurtman A
    Vaccine; 2024 Sep; 42(22):126041. PubMed ID: 38853036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of Respiratory Syncytial Virus disease among infants in Canada: a simulation study.
    Shoukat A; Abdollahi E; Galvani AP; Halperin SA; Langley JM; Moghadas SM
    Lancet Reg Health Am; 2023 Dec; 28():100629. PubMed ID: 38026446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of RSVpreF vaccine and nirsevimab for the prevention of respiratory syncytial virus disease in Canadian infants.
    Gebretekle GB; Yeung MW; Ximenes R; Cernat A; Simmons AE; Killikelly A; Siu W; Rafferty E; Brousseau N; Tunis M; Tuite AR
    Vaccine; 2024 Aug; 42(21):126164. PubMed ID: 39079810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus-Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.
    Fleming-Dutra KE; Jones JM; Roper LE; Prill MM; Ortega-Sanchez IR; Moulia DL; Wallace M; Godfrey M; Broder KR; Tepper NK; Brooks O; Sánchez PJ; Kotton CN; Mahon BE; Long SS; McMorrow ML
    MMWR Morb Mortal Wkly Rep; 2023 Oct; 72(41):1115-1122. PubMed ID: 37824423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Equivalent immunogenicity across three RSVpreF vaccine lots in healthy adults 18-49 years of age: Results of a randomized phase 3 study.
    Baker J; Aliabadi N; Munjal I; Jiang Q; Feng Y; Brock LG; Cooper D; Anderson AS; Swanson KA; Gruber WC; Gurtman A
    Vaccine; 2024 May; 42(13):3172-3179. PubMed ID: 38616438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact and cost-effectiveness of strategies to prevent respiratory syncytial virus (RSV) disease in Vietnam: A modelling study.
    Do LAH; Le NTN; Mahmud S; Mulholland K; Pecenka C; Clark A
    Vaccine; 2023 Nov; 41(46):6782-6790. PubMed ID: 37690873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the potential impact and cost-effectiveness of respiratory syncytial virus (RSV) prevention strategies for infants in Argentina.
    Guiñazú G; Dvorkin J; Mahmud S; Baral R; Pecenka C; Libster R; Clark A; Caballero MT
    Vaccine; 2024 Oct; 42(23):126234. PubMed ID: 39154512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prefusion F Protein-Based Respiratory Syncytial Virus Immunization in Pregnancy.
    Simões EAF; Center KJ; Tita ATN; Swanson KA; Radley D; Houghton J; McGrory SB; Gomme E; Anderson M; Roberts JP; Scott DA; Jansen KU; Gruber WC; Dormitzer PR; Gurtman AC
    N Engl J Med; 2022 Apr; 386(17):1615-1626. PubMed ID: 35476650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Respiratory Syncytial Virus Prefusion F Subunit Vaccine: First Approval of a Maternal Vaccine to Protect Infants.
    Syed YY
    Paediatr Drugs; 2023 Nov; 25(6):729-734. PubMed ID: 37831328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants.
    Kampmann B; Madhi SA; Munjal I; Simões EAF; Pahud BA; Llapur C; Baker J; Pérez Marc G; Radley D; Shittu E; Glanternik J; Snaggs H; Baber J; Zachariah P; Barnabas SL; Fausett M; Adam T; Perreras N; Van Houten MA; Kantele A; Huang LM; Bont LJ; Otsuki T; Vargas SL; Gullam J; Tapiero B; Stein RT; Polack FP; Zar HJ; Staerke NB; Duron Padilla M; Richmond PC; Koury K; Schneider K; Kalinina EV; Cooper D; Jansen KU; Anderson AS; Swanson KA; Gruber WC; Gurtman A;
    N Engl J Med; 2023 Apr; 388(16):1451-1464. PubMed ID: 37018474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The potential public health impact of the respiratory syncytial virus prefusion F protein vaccine in people aged ≥60 years in Japan: results of a Markov model analysis.
    Kurai D; Mizukami A; Preckler V; Verelst F; Molnar D; Matsuki T; Ho Y; Igarashi A
    Expert Rev Vaccines; 2024; 23(1):303-311. PubMed ID: 38426479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimating the cost-effectiveness of maternal vaccination and monoclonal antibodies for respiratory syncytial virus in Kenya and South Africa.
    Koltai M; Moyes J; Nyawanda B; Nyiro J; Munywoki PK; Tempia S; Li X; Antillon M; Bilcke J; Flasche S; Beutels P; Nokes DJ; Cohen C; Jit M
    BMC Med; 2023 Mar; 21(1):120. PubMed ID: 37004062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Randomized Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine.
    Walsh EE; Falsey AR; Scott DA; Gurtman A; Zareba AM; Jansen KU; Gruber WC; Dormitzer PR; Swanson KA; Radley D; Gomme E; Cooper D; Schmoele-Thoma B
    J Infect Dis; 2022 Apr; 225(8):1357-1366. PubMed ID: 34932102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Respiratory syncytial virus vaccination and immunoprophylaxis: realising the potential for protection of young children.
    Pecenka C; Sparrow E; Feikin DR; Srikantiah P; Darko DM; Karikari-Boateng E; Baral R; Vizzotti C; Rearte A; Jalang'o R; Fleming JA; Martinón-Torres F; Karron RA
    Lancet; 2024 Sep; 404(10458):1157-1170. PubMed ID: 39265588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of potential infant vaccination against respiratory syncytial virus infection in The Netherlands.
    Meijboom MJ; Rozenbaum MH; Benedictus A; Luytjes W; Kneyber MC; Wilschut JC; Hak E; Postma MJ
    Vaccine; 2012 Jun; 30(31):4691-700. PubMed ID: 22561315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Respiratory syncytial virus immunization program for the United States: impact of performance determinants of a theoretical vaccine.
    Régnier SA
    Vaccine; 2013 Sep; 31(40):4347-54. PubMed ID: 23896421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact and cost-effectiveness analyses of vaccination for prevention of respiratory syncytial virus disease among older adults in Ontario: A Canadian Immunization Research Network (CIRN) study.
    Shoukat A; Bawden CE; Röst G; LeBlanc JJ; Galvani AP; Langley JM; Moghadas SM
    Vaccine; 2024 Mar; 42(7):1768-1776. PubMed ID: 38368226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.